Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(1997): Banac S+, Acta Paediatr 86(8), 899
(1997): Emile JF+, JPathol181(1), 25
(1997): Hashimoto T, Kekkaku 72(11), 629
(1996): Casanova JL+, Pediatrics 98(4), 774
(1996): Jouanguy E+, NEnglJMed335(26), 1956
(1986): Fasth A, Lakartidningen 83(11), 969
(1982): Trevenen CL+, Can Med Assoc J 127(6), 502
(1980): Perelman R+, Sem Hop 56(9-10), 480
Hepatotoxicity
(1991): Simma B+, Eur J Pediatr 150(6), 423
Hypersensitivity
(1998): Grange JM, Commun Dis Public Health 1(2), 84
(1998): Lowry PW+, JInfectDis178(1), 138
Infections
(2004): Zwolska Z+, Pneumonol Alergol Pol 72(11-1), 505
Injection-site abscess
(2002): Turnbull FM+, Clin Infect Dis 34(4), 447
(1998): Grange JM, Commun Dis Public Health 1(2), 84
Injection-site ulceration
(1997): Pankowska A+, Pneumonol Alergol Pol 65(11-1), 761
(1991): Spiess H, Offentl Gesundheitswes 53(8-9), 631
Myalgia/Myositis/Myopathy/Myotoxicity
(2006): Franco-Paredes+, Am J Med 119(6), 470
Neurotoxicity
(1999): Wilmshurst JM+, Eur J Paediatr Neurol 3(6), 277
(1982): Katznelson D+, Postgrad Med J 58(682), 496
Tumors
(1993): Wolff M+, Monatsschr Kinderheilkd 141(5), 409
BECLOMETHASONE
Trade names: Beconase AQ (GSK); Qvar (3M); Vanceril
(Schering)
Indications: Allergic rhinitis, Asthma
Category: Corticosteroid, inhaled
Half-life: N/A
Clinically important, potentially hazardous interactions
with: diuretics, estrogens, ketoconazole, live vaccines, oral
contraceptives, phenytoin, rifampin, warfarin
Reactions
Skin
Atrophy
(1999): Konietzko N, Dtsch Med Wochenschr 124(28-2), 882
Bruising
(2001): Berend N+, Respirology 6(3), 237
(1999): Lipworth BJ, Arch Intern Med 159(9), 941
(1999): Malo JL+, EurRespirJ13(5), 993
Dermatitis
(2000): Tani A+, Contact Dermatitis 43(6), 363
Eczema
(2003): Kilpio K+, Allergy 58(11), 1131
Edema
Mucosal
Oral candidiasis
(2003): Fukushima C+, Ann Allergy Asthma Immunol 90(6), 646
(1998): Reed CE+, J Allergy Clin Immunol 101, 14
Perianal ulcerations
(2002): Adams BB+, Cutis 69, 67
Stomatitis
(1990): Yamaguchi M+, Kyobu Shikkan Gakkai Zasshi (Japanese)
28, 1410
Eyes
Cataract
(2002): Dendukuri N+, Br J Clin Pharmacol 54(1), 59
(2001): Jick SS+, Epidemiology 12(2), 229
(1999): Lipworth BJ, Arch Intern Med 159(9), 941
Glaucoma
(2002): Dendukuri N+, Br J Clin Pharmacol 54(1), 59
(1999): Lipworth BJ, Arch Intern Med 159(9), 941
(1999): Mitchell P+, Ophthalmology 106(12), 2301
Other
Adverse effects (sic)
(2003): Coghlan D+, Paediatr Drugs 5(10), 685 (rare)
(2003): Delacourt C+, Respir Med 97, S27
(2003): Kunkel G+, Respiration 70(4), 399
(2003): Lumry W+, Allergy Asthma Proc 24(3), 203
(2003): Shah SS+, Cochrane Database Syst Rev LD(2), CD00
(2001): Reichel W+, Int J Clin Pract 55(2), 100
(2001): Terzano C+, Eur Rev Med Pharmacol Sci 5(1), 17
Candidiasis
(2003): Randell TL+, Paediatr Drugs 5(7), 481 (rare)
(2002): Prenner BM+, Eur Rev Med Pharmacol Sci 6(4), 61
Cough
(2003): Dubus JC+, Fundam Clin Pharmacol 17(5), 627
Hypersensitivity
(2002): Sommer S+, Br J Dermatol 147(2), 266
Myalgia/Myositis/Myopathy/Myotoxicity
Side effects (sic)
(2004): May C+, Monaldi Arch Chest Dis 61(3), 162
BENACTYZINE
Trade name: Deprol
Indications: Depression, anxiety
Category: Muscarinic antagonist
Half-life: N/A
Deprol is benactyzine and meprobamate
Note: Most of the adverse reactions are due to meprobamate (which
see)
Reactions
BENACTYZINE 61
Skin
Angioedema
Bullous dermatitis
Edema
Erythema multiforme
Exanthems
Exfoliative dermatitis
Fixed eruption
Petechiae
Pruritus
Urticaria
Mucosal
Stomatitis
Xerostomia
Eyes
Visual disturbances
(1982): Brown B+, Aviat Space Environ Med 53(11), 1123
Other
Anaphylactoid reactions/Anaphylaxis